1. Introduction

Oncolytic viruses are promising new agents for cancer treatment. They can kill cancer cells directly through infection or indirectly through activation of the immune system ^[1][2][1,2]. For the most effective virotherapy, elimination of malignant cells with a combination of both direct and indirect destruction is desirable. Like all viruses, oncolytic viruses use specific receptors to bind to and enter host cells. This review describes the tendency of tumor cells to overexpress certain viral receptors, but it also shows that, to varying degrees, these receptors are also expressed in many normal cells. However, regardless of whether cells are normal or malignant, absence of receptors for a particular virus makes the cells resistant to this virus infection. So, for better identification of individual patients who are most likely to benefit from virotherapy, their tumor cells should be screened for the presence of virus receptors. For many oncolytic viruses, such receptors are well characterized. Thus, simple tests that evaluate protein or RNA levels in tumor tissue could provide information about expression levels of a virus receptor.

Receptor mediated virus entry into a cell is only the first step in viral infection. Next, the virus must break through the cellular antiviral defense system, which usually effectively protects normal cells from any virus infection. Key players in such protection are interferons (IFNs); they help cells detect the presence of a virus and, in response, restrict proliferation, slow down metabolic processes, and trigger apoptosis ^[3][4][3,4]. However, malignant cells frequently have dysfunctional IFN pathways. Such dysfunction helps them to evade the immune system and survive, thus promoting tumor growth. The same IFN defects that help cancer cells escape immune surveillance make them vulnerable to virus infection [5]. Nevertheless, not all malignant cells have dysfunctional IFN pathways. Some of them can produce and/or respond to IFN signals and protect themselves from a virus infection. So, theoretically, even if a cancer cell had receptors for a particular oncolytic virus it still could be resistant to infection by the virus.

Some viruses require cells to express processing enzymes that modify or cleave the viral proteins necessary for the formation of mature infectious virions. Thus, fusion protein in paramyxoviruses is synthesized as an inactive precursor and is activated through proteolytic cleavage by the cellular protease. Without such cleavage the virus is unable to sustain infection. For MV, this activating protease is furin [6] and for SeV it can be a number of serine proteases (TPSB2 ^[7][8][9][7,8,9], PRSS1 [10], PLG [11], F10 [12], and TMPRSS2 [13]). Some of these proteases are overexpressed in cancer cells ^[14][15][16][14,15,16]. In addition to those listed, the expression levels of other host genes influence vulnerability of cancer cells to a virus infection. FigureFigure 1 1 illustrates factors necessary for a cell to become vulnerable to paramyxovirus infection.

Figure 1. Factors influencing cells’ vulnerability to paramyxovirus infection. The host cell needs to (1) express virus receptors (2) have a malfunctioning IFN pathway, (3) express proteases responsible for proteolytic activation of virus fusion rotein, and (4) have other genes that require further identification.

To predict if a patient is likely to respond to oncolytic virotherapy, testing for the presence of virus receptors in tumor tissue is not sufficient. Additional tests are also needed to reveal the presence of impaired IFN signaling in the patient’s cancer cells, and the expression of virus processing enzymes and yet to be identified other proteins that accommodate virus infection. Currently, such tests are commercially unavailable and need to be developed to optimize patient selection protocols for future clinical trials.

Oncolytic paramyxoviruses might become powerful anticancer agents ^[17][18][19][17,18,19]. FigureFigure 2 2 shows the life cycle of the viruses, which can trigger syncytium (a polykarion) formation that protects virions from host neutralizing antibodies during intratumor virus replication and spreading.

Figure 2. A visual representation of the cell cycle of measles virus (MV) and Sendai virus (SeV). Both viruses belong to the Paramyxoviridae family, but MV belongs to the Morbillivirus genus and SeV to the Respirovirus genus. The life cycles of MV and SeV are very similar, but there are several important differences. Their attachment to host cells occurs through different cell entry receptors and different viral cell attachment proteins. The MV virus uses an H protein with hemagglutinin activity, while SeV uses the HN protein with hemagglutinin (H) and neuraminidase (N) activities. In addition to these proteins, the genomes of these viruses encode 5 structural proteins and accessary proteins. The main structural proteins for both viruses are: Nucleoprotein (N), Phosphoprotein (P), Matrix protein (M), Fusion protein (F), and Large Protein (L). The MV genome encodes two non-structural proteins, C and V, [20], while the SeV genome encodes a set of non-structural proteins, collectively referred as C-proteins (C’, C, Y1, Y2, V, W) [21]. Viral replication for MV and SeV follows a negative-stranded RNA virus replication model in which genomic RNA (minus strand) is used as a template to create a copy of positive sense RNA, employing the RNA-dependent RNA polymerase embedded in the virion. The plus RNA is further used as a template for making multiple copies of the minus RNA. The plus RNA is also translated by the host’s ribosomes, producing all viral proteins. Viruses are then assembled from these proteins along with genomic RNA and budded from the host cell. Both MV and SeV can form syncytia by fusing neighboring infected and non-infected cells into a polykayion.

So, two related processes can occur: Efficient intratumor virus spread and the resulting mass death of malignant cells. In general, oncolytic paramyxoviruses stimulate strong innate and adaptive anticancer immune responses by generating multiple danger signals. They are potent inducers of IFN and other immuno-stimulating cytokines, and they efficiently induce anticancer activity of natural killer cells, dendritic cells, and cytotoxic T lymphocytes [18]. Finally, the viruses require proteolytic cleavage of their fusion proteins by cellular serine proteases, which are sometimes overexpressed in cancer cells ^[14][15][16][14,15,16], and could add an additional level of specificity to viral oncolytic activity. Moreover, the gene that encodes a fusion protein in the paramyxovirus genome can be replaced with a constructed fusion protein that could be processed by tumor-associated matrix metalloproteases.

2. Measles Virus as an Oncolytic Agent

MV (Box 1, Figure 3) causes a highly contagious disease transmitted by respiratory aerosols that can trigger severe immunosuppression and even immune amnesia.

Figure 3. Schematic representation of the MV genome (A), virion (B) and host cell entry receptors (C). The RNA genome (gRNA) contains six transcription units that codes 6 main structural proteins: nucleoprotein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), hemagglutinin (H), and large protein (L) RNA dependent RNA polymerase (RdRp). The viral genome also codes the nonstructural V and C proteins, which are antagonists of host innate immunity. The transcription units for each structural gene are separated by non-transcribed trinucleotide intergenic sequences and together are flanked by short leader and trailer sequences containing the genomic promoter (on the minus strand) and the antigenomic promoter (on the plus strand). Inside the virion, genomic RNA forms a complex with N, L, and P proteins. The virus is enveloped by a lipid membrane that has glycoproteins H and F associated with it as virion surface proteins. These proteins coordinate how the virus finds cells and enters them. For H protein, three receptors have been identified: Complement regulatory molecule CD46, the cell adhesion molecule nectin-4 and the signaling lymphocyte activation molecule (SLAM). MV wild-type strains use SLAM and nectin-4 as cell entry receptors. Vaccine strains and a small fraction of wild type strains, in addition, use CD46 as a cell entry receptor.

Box 1. Measles Virus (MV).

Significant efforts by virologists in the second half of the 20th century were focused on finding a safe and effective vaccine against MV. In 1954, one MV isolated strain, when passaged in cell culture, gradually lost its pathogenicity, and became attenuated. From this attenuated variant of the virus, one of the first vaccine strain (Edmonston, denoted in the following text as MV-Edm) was obtained. Further passages of MV-Edm generated the more attenuated Schwarz and Moraten strains, which are still in use for vaccination against measles ^[23][24][24,25].

During the 20th century clinicians reported on isolated cases where measles disease relieved or caused remission of certain malignancies. Reports include descriptions of the regression of a number of hematological malignancies that took place after MV infection (reviewed in ^[25][26]). At the end of the century, virologists and oncologists started to investigate oncolytic properties of attenuated MV strains that are incapable of causing serious infection.

MV-Edm and its derivatives were the primary strains tested as oncolytic agents ^[26][27][27,28]. These strains can infect and kill a wide variety of cancer cells in vitro and in vivo. They are currently being investigated preclinically and in clinical trials for treatment of a large spectrum of malignancies, including ovarian, breast, head and neck cancers, as well as glioblastoma, multiple myeloma, mesothelioma, and T-cell lymphoma ^[26][27][27,28]. A virus with oncolytic properties can be delivered not only locally intratumorally, but also systemically, including by intraperitoneal and intravenous injection routes. In some trials patients survival compared favorably with that of historical controls and the side effects of the virotherapy were mainly mild ^[26][27][27,28].

3. Sendai virus as an oncolytic agent

Sendai virus (SeV) causes respiratory infections in mice and other rodents (Box 2). However, it is not associated with any human disease and can be a safe oncolytic agent. Safety of SeV for humans, including small children, has been confirmed experimentally. The virus in the form of nasal drops has been tested as a vaccine against human parainfluenza virus type 1, which causes respiratory symptoms in humans. Testing in adults and children demonstrated that experimental administration of wild type SeV triggered production of neutralizing antibodies towards human parainfluenza virus type 1 and was well tolerated ^[28][29] [29],[30]. SeV showed an excellent safety profile in a clinical trial ^[30][31].

Box 2. Sendai Virus (SeV)

Wild-type SeV can infect a large spectrum of malignant cells ex vivo ^[34][35]. A pilot study demonstrated that some canine (dog) cancers such as mastocytomas can be eradicated with the help of SeV injections ^[35][36]. However, the virus is infectious for laboratory rodents. Therefore, for studying SeV oncolytic properties in a rodent model, a set of viral constructs that are nonpathogenic for experimental mice was created. They were tested in animals bearing a variety of human xenograft tumors including sarcoma, melanoma, pancreas, colon, hepatocellular and prostate carcinomas. The SeV constructs promoted growth suppression or even complete tumor eradication of these malignancies ^{[36][37][38][39]}[37][38][39][40], and elimination of established brain tumors ^[40][41].

In addition, UV- inactivated SeV virions have immune-stimulating properties: in animal model and they promote tumor regression of colon ^[41][42][42][43], bladder ^[43][44] and kidney ^[44][45] cancers. Other animal models these virions contribute to the eradication of human prostate cancer ^[45][46]. 

Oncolytic mechanism of Sendai virus action is discussed in detail in a number of publications ^[46][47][48][47][48][49].

So far, SeV has not been widely tested in clinical settings. An attempt to treat one case of human leukemia with a set of viruses, including SeV, was undertaken in 1964 at the Clinical Research Center of University Hospitals of Cleveland. Short-term remission in one patient affected by acute leukemia was observed after intravenous virus injection ^[49][50]. A few patients affected by various malignancies were treated with intradermally or intratumorally injected SeV in Moscow (Russia) in the 1990s. In a small fraction of patients treated with the virus, primary tumors and metastases disappeared, even when virotherapy was a monotherapy. These patients experienced a pronounced long-term remission that sometimes lasted more than 5-10 years ^[50][51].

4. Conclusions

The cell entry receptors of oncolytic paramyxoviruses are represented by different types of molecules. They are proteins for measles virus and sialylated proteins or glycans for Sendai virus.The molecules that serve as viral receptors for these viruses have extremely variable expression patterns in malignancies. A reliable predictive model for categorization of tumor cells according to their susceptibility to oncolytic virus infection requires many input parameters, which include but are not limited to expression patterns of viral receptors. Most likely, gene signatures of several immune-related genes such as IRGs and certain type II transmembrane serine proteases may serve as useful input parameters for predictive models. The creation and verification of a multi-parameter predictive model should have measurable therapeutic benefits for oncolytic virotherapy.